Contact

KiraLOGIC · Design + learn

Which protective edits belong together?

KiraLOGIC prioritizes combinations we build and test against tumor suppression. Experimental results inform what we select next.

See the design loop

Illustrative protection combinations

From evidence to experiments

A focused set to build and test.

01Explore

Possible gene-edit combinations.

02Prioritize

KiraLOGIC

Predicted performance · Uncertainty · Diversity

Illustrative design A: a blue cell with purple headphones.
Design A
Illustrative design B: a blue cell with silver headphones.
Design B
Illustrative design C: a blue cell with blue headphones.
Design C

03Build + test

Same challenge.
Different protection combinations.

Design A
Design A: a prominent blue CAR-T cell with purple headphones in the same suppressive tumor environment.
Design B
Design B: a prominent blue CAR-T cell with silver headphones in the same suppressive tumor environment.
Design C
Design C: a prominent blue CAR-T cell with blue headphones in the same suppressive tumor environment.

Tumor killing · Cell survival · Repeat activity

04Learn

KiraGen experimental results inform the next selection.

Conceptual workflow. Designs are illustrative.

Selected designs are built as separate engineered cell products and tested under the same suppressive challenge, including in relevant patient-derived models.

80candidate genes
6edits
~300Mcombinations

Illustrative six-edit search space, before biological and product constraints. KiraLOGIC can prioritize different combination sizes.

How the example is calculated

Choosing exactly six distinct genes from 80 gives 300,500,200 unordered combinations. This illustrates the search space, not a count of feasible or tested designs. KGEN-001 contains six coordinated gene edits; six is not a fixed requirement for subsequent designs.

What we know. What we test next.

Evidence today

~4×

Enrichment of high-performing
pairs vs random

Retrospective · Lower-order · GBM context

Higher-order prospective performance remains to be tested.

About this benchmark

Company-reported retrospective benchmark in a GBM context. The result concerns lower-order gene-edit pairs and does not establish prospective performance for complete higher-order designs.

Next test · 1H 2027

Prospective selection.

Compare higher-order designs selected by KiraLOGIC with prespecified expert-guided and computational baselines.

Matched experimental capacity

Planned comparison · Results pending

Every test informs the next selection.

We connect each design with the editing achieved, cell state, and measured function.

Phenomena, Reflector Bio’s pretrained model, provides a starting representation. KiraGen contributes combination-selection logic and experimental measurements.

A fully visible bright-blue CAR-T cell wearing charcoal noise-cancelling headphones, surrounded by softly focused tumor tissue. Conceptual illustration of engineered resistance to suppression.

Our first design. Our next decisions.

KGEN-001 is our first design.

KGEN-001 was designed from human glioblastoma biology before KiraLOGIC existed. Precursor and related cell designs help establish the initial experimental reference.

KiraLOGIC prioritizes what we build and test next.

Explore KGEN-001

Partner on the next cell-therapy design.

Prioritize and test protective edit combinations against a defined biological challenge.

Discuss a collaboration